NICE warms to saying yes to Simponi for RA
This article was originally published in Scrip
Executive Summary
By agreeing a patient access scheme with the UK Department of Health, Merck has managed to overturn a previous recommendation from the National Institute of Health and Clinical Excellence (NICE), the heath technology assessment agency covering England Wales, regarding the use of Simponi golimumab in combination with methotrexate to treat rheumatoid arthritis patients that have responded inadequately to conventional disease modifying antirheumatic drugs.